{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T02:25:57Z","timestamp":1697509557449},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T00:00:00Z","timestamp":1624924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00105-021-04844-y","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T16:02:51Z","timestamp":1624982571000},"page":"686-691","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systemische Therapie der mittelschweren\/schweren Hidradenitis suppurativa"],"prefix":"10.1007","volume":"72","author":[{"given":"A","family":"Pinter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Mrowietz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Volz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,6,29]]},"reference":[{"issue":"11","key":"4844_CR1","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1111\/ijd.14596","volume":"58","author":"R Andre","year":"2019","unstructured":"Andre\u00a0R, Marescassier\u00a0H, Gabay\u00a0C et al (2019) Long-term therapy with anakinra in hidradenitis suppurativa in three patients. Int J Dermatol 58(11):e208\u2013e209","journal-title":"Int J Dermatol"},{"issue":"1","key":"4844_CR2","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/j.1365-2133.2010.10071.x","volume":"164","author":"J Boer","year":"2011","unstructured":"Boer\u00a0J, Nazary\u00a0M (2011) Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a\u00a0misnomer? Br J Dermatol 164(1):170\u2013175","journal-title":"Br J Dermatol"},{"key":"4844_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20097","author":"Y Cao","year":"2021","unstructured":"Cao\u00a0Y, Hong\u00a0F, Conlon\u00a0DM et\u00a0al (2021) Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa. Br J Dermatol. https:\/\/doi.org\/10.1111\/bjd.20097","journal-title":"Br J Dermatol"},{"key":"4844_CR4","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/ced.14388","volume":"46","author":"RD Caposiena Caro","year":"2021","unstructured":"Caposiena Caro\u00a0RD, Molinelli\u00a0E, Brisigotti\u00a0V et\u00a0al (2021) Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation. Clin Exp Dermatol 46:96\u2013102","journal-title":"Clin Exp Dermatol"},{"key":"4844_CR5","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1111\/ced.12933","volume":"41","author":"C Dessinioti","year":"2016","unstructured":"Dessinioti\u00a0C, Zisimou\u00a0C, Tzanetakou\u00a0V et al (2016) Oral clindamycin and rifampicin combination therapy for hidradenitis suppurativa: a\u00a0prospective study and 1\u2011year follow-up. Clin Exp Dermatol 41:852\u2013857","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"4844_CR6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew\u00a0JW, Navrazhina\u00a0K, Grand\u00a0D et al (2020) The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J\u00a0Am Acad Dermatol 83(5):1341\u20131348","journal-title":"J Am Acad Dermatol"},{"key":"4844_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1159\/000228334","volume":"219","author":"G Gener","year":"2009","unstructured":"Gener\u00a0G, Canoui-Poitrine\u00a0F, Revuz\u00a0JE et al (2009) Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a\u00a0series of 116\u00a0consecutive patients. Dermatology 219:148\u2013154","journal-title":"Dermatology"},{"issue":"2","key":"4844_CR8","first-page":"139","volume":"7","author":"V Harde","year":"2009","unstructured":"Harde\u00a0V, Mrowietz\u00a0U (2009) Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab. J\u00a0Dtsch Dermatol Ges 7(2):139\u2013141","journal-title":"J Dtsch Dermatol Ges"},{"key":"4844_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000446812","volume":"29","author":"S Hessam","year":"2016","unstructured":"Hessam\u00a0S, Sand\u00a0M, Georgas\u00a0D et\u00a0al (2016) Microbial profile and antimicrobial susceptibility of bacteria found in inflammatory hidradenitis suppurativa lesions. Skin Pharmacol Physiol 29:161\u2013167","journal-title":"Skin Pharmacol Physiol"},{"issue":"11","key":"4844_CR10","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1001\/jamadermatol.2017.2392","volume":"153","author":"C Houriet","year":"2017","unstructured":"Houriet\u00a0C, Seyed Jafari\u00a0SM, Thomi\u00a0R et\u00a0al (2017) Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases. JAMA Dermatol 153(11):1195\u20131197","journal-title":"JAMA Dermatol"},{"key":"4844_CR11","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","volume":"39","author":"GB Jemec","year":"1998","unstructured":"Jemec\u00a0GB, Wendelboe\u00a0P (1998) Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J\u00a0Am Acad Dermatol 39:971\u2013974","journal-title":"J Am Acad Dermatol"},{"key":"4844_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1093\/jac\/dkv361","volume":"71","author":"O Join-Lambert","year":"2016","unstructured":"Join-Lambert\u00a0O, Coignard-Biehler\u00a0H, Jais\u00a0JP et al (2016) Efficacy of ertapenem in severe hidradenitis suppurativa: a\u00a0pilot study in a\u00a0cohort of 30\u00a0consecutive patients. J\u00a0Antimicrob Chemother 71:513\u2013520","journal-title":"J Antimicrob Chemother"},{"key":"4844_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000321716","volume":"222","author":"O Join-Lambert","year":"2011","unstructured":"Join-Lambert\u00a0O, Coignard\u00a0H, Jais\u00a0JP et al (2011) Efficacy of rifampin-moxifloxacin-metronidazole combination therapy in hidradenitis suppurativa. Dermatology 222:49\u201358","journal-title":"Dermatology"},{"key":"4844_CR14","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15459","author":"AR Jorgensen","year":"2021","unstructured":"Jorgensen\u00a0AR, Yao\u00a0Y, Thomsen\u00a0SF et\u00a0al (2021) Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. Int J Dermatol. https:\/\/doi.org\/10.1111\/ijd.15459","journal-title":"Int J Dermatol"},{"issue":"5","key":"4844_CR15","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball\u00a0AB, Okun\u00a0MM, Williams\u00a0DA et\u00a0al (2016) Two phase 3 trials of adalimumab for hidradenitis suppurativa. N\u00a0Engl J Med 375(5):422\u2013434","journal-title":"N Engl J Med"},{"key":"4844_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1080\/17512433.2020.1762571","volume":"13","author":"C Marasca","year":"2020","unstructured":"Marasca\u00a0C, Tranchini\u00a0P, Marino\u00a0V et\u00a0al (2020) The pharmacology of antibiotic therapy in hidradenitis suppurativa. Expert Rev Clin Pharmacol 13:521\u2013530","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"4","key":"4844_CR17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/00054725-200111000-00008","volume":"7","author":"F Martinez","year":"2001","unstructured":"Martinez\u00a0F, Nos\u00a0P, Benlloch\u00a0S et\u00a0al (2001) Hidradenitis suppurativa and Crohn\u2019s disease: response to treatment with infliximab. Inflamm Bowel Dis 7(4):323\u2013326","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"4844_CR18","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/bjd.12884","volume":"171","author":"L Matusiak","year":"2014","unstructured":"Matusiak\u00a0L, Bieniek\u00a0A, Szepietowski\u00a0JC (2014) Acitretin treatment for hidradenitis suppurativa: a\u00a0prospective series of 17\u00a0patients. Br J Dermatol 171(1):170\u2013174","journal-title":"Br J Dermatol"},{"issue":"4","key":"4844_CR19","first-page":"e13756","volume":"33","author":"M Megna","year":"2020","unstructured":"Megna\u00a0M, Ruggiero\u00a0A, Di Guida\u00a0A et\u00a0al (2020) Ixekizumab: an efficacious treatment for both psoriasis and hidradenitis suppurativa. Dermatol Ther 33(4):e13756","journal-title":"Dermatol Ther"},{"key":"4844_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ad.2018.03.012","volume":"109","author":"P Mendes-Bastos","year":"2018","unstructured":"Mendes-Bastos\u00a0P, Martorell\u00a0A, Magina\u00a0S (2018) Ertapenem for the treatment of hidradenitis suppurativa: How much do we need it? Actas Dermosifiliogr 109:582\u2013583","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"4844_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.19136","volume":"183","author":"G Murray","year":"2020","unstructured":"Murray\u00a0G, Hollywood\u00a0A, Kirby\u00a0B et\u00a0al (2020) Dapsone therapy for hidradenitis suppurativa. Br J Dermatol 183(4):767\u2013768","journal-title":"Br J Dermatol"},{"key":"4844_CR22","first-page":"1","volume":"26","author":"N Patel","year":"2019","unstructured":"Patel\u00a0N, McKenzie\u00a0SA, Harview\u00a0CL et\u00a0al (2019) Isotretinoin in the treatment of hidradenitis suppurativa: a\u00a0retrospective study. J\u00a0Dermatolog Treat 26:1\u20133","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"4844_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/bjd.17822","volume":"181","author":"L Prussick","year":"2019","unstructured":"Prussick\u00a0L, Rothstein\u00a0B, Joshipura\u00a0D et al (2019) Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol 181(3):609\u2013611","journal-title":"Br J Dermatol"},{"issue":"6","key":"4844_CR24","doi-asserted-by":"publisher","first-page":"e14054","DOI":"10.1111\/dth.14054","volume":"33","author":"EM S\u00e1nchez-Mart\u00ednez","year":"2020","unstructured":"S\u00e1nchez-Mart\u00ednez\u00a0EM, Garc\u00eda\u2010Ruiz\u00a0R, Moneva\u2010L\u00e9niz\u00a0LM et al (2020) Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction. Dermatol Ther 33(6):e14054","journal-title":"Dermatol Ther"},{"key":"4844_CR25","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1055\/a-0885-5152","volume":"45","author":"A Schuch","year":"2019","unstructured":"Schuch\u00a0A, Absmaier-Kijak\u00a0M, Volz\u00a0T (2019) Acne inversa\/Hidradenitis suppurativa \u2013 Von der Pathogenese zur Therapie. Akt Dermatol 45:277\u2013287","journal-title":"Akt Dermatol"},{"key":"4844_CR26","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1159\/000182261","volume":"218","author":"A Soria","year":"2009","unstructured":"Soria\u00a0A, Canoui-Poitrine\u00a0F, Wolkenstein\u00a0P et al (2009) Absence of efficacy of oral isotretinoin in hidradenitis suppurativa: aretrospective study based on patients\u2019 outcome assessment. Dermatology 218:134\u2013135","journal-title":"Dermatology"},{"key":"4844_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.12.089","author":"KR Van Straalen","year":"2021","unstructured":"Van Straalen\u00a0KR, Tzellos\u00a0T, Guillem\u00a0P et\u00a0al (2021) The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa; results of a prospective European cohort study. J\u00a0Am Acad Dermatol. https:\/\/doi.org\/10.1016\/j.jaad.2020.12.089","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"4844_CR28","first-page":"155","volume":"150","author":"R Verdolini","year":"2015","unstructured":"Verdolini\u00a0R, Simonacci\u00a0F, Menon\u00a0S et al (2015) Alitretinoin: a\u00a0useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age. G\u00a0Ital Dermatol Venereol 150(2):155\u2013162","journal-title":"G Ital Dermatol Venereol"},{"issue":"4","key":"4844_CR29","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/ijd.15286","volume":"60","author":"I Wohlmuth-Wieser","year":"2021","unstructured":"Wohlmuth-Wieser\u00a0I, Alhusayen\u00a0R (2021) Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. Int J Dermatol 60(4):e140\u2013e141","journal-title":"Int J Dermatol"},{"issue":"4","key":"4844_CR30","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1159\/000329023","volume":"222","author":"S Yazdanyar","year":"2011","unstructured":"Yazdanyar\u00a0S, Boer\u00a0J, Ingvarsson\u00a0G et\u00a0al (2011) Dapsone therapy for hidradenitis suppurativa: a\u00a0series of 24\u00a0patients. Dermatology 222(4):342\u2013346","journal-title":"Dermatology"},{"key":"4844_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis\u00a0CC, Desai\u00a0N, Emtestam\u00a0L et\u00a0al (2015) European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J\u00a0Eur Acad Dermatol Venereol 29:619\u2013644","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-021-04844-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-021-04844-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T07:03:02Z","timestamp":1627542182000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-021-04844-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,29]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4844"],"URL":"https:\/\/doi.org\/10.1007\/s00105-021-04844-y","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,29]]},"assertion":[{"value":"19 May 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Pinter: Berater- und\/oder Vortragshonorare und\/oder Durchf\u00fchrung klinischer Studien f\u00fcr: AbbVie, Almirall-Hermal, Amgen, Biogen Idec, BioNTech, Boehringer-Ingelheim, Celgene, Celltrion, GSK, Eli-Lilly, Galderma, Hexal, Janssen, LEO-Pharma, MC2, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pascoe, Pfizer, Tigercat Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Sanofi-Genzyme, Schering-Plough und UCB Pharma. U.\u00a0Mrowietz<b>:<\/b> Berater und\/oder Redner und\/oder Empf\u00e4nger von Forschungsunterst\u00fctzungen und\/oder Teilnehmer an klinischen Studien f\u00fcr folgende Firmen: AbbVie, Aditxt, Almirall, Amgen, Aristea, Boehringer-Ingelheim, Bristol-Myers Squibb, Celgene, Dr. Reddy\u2019s, Eli Lilly, Foamix, Formycon, Immunic, Janssen, LEO Pharma, Medac, MetrioPharm, Novartis, Phi-Stone, Pierre Fabre, Sanofi-Aventis, UCB. T.\u00a0Volz: Berater- und\/oder Vortragshonorare und\/oder Durchf\u00fchrung klinischer Studien f\u00fcr: AbbVie, Almirall-Hermal, Beiersdorf, HiPP, La Roche Posay, Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}